Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc.
780 Dedham Street, Suite 800
Canton, MA 02021
(781) 713–3699Website: https://www.collegiumpharma.com/Careers: https://careers-collegiumpharma.icims.com
Latest News
- Collegium Receives FDA Approval for Xtampza ER, an Analgesic with Abuse-Deterrent Properties - April 26, 2016
- Collegium Announces FDA Tentative Approval for Xtampza ER, a Novel Abuse-Deterrent Analgesic for Chronic Pain - November 9, 2015
- Collegium Provides Update on FDA Review of Xtampza ER, an Abuse-Deterrent Analgesic for the Treatment of Chronic Pain - October 12, 2015
- Collegium Announces FDA Advisory Committees Unanimously Recommend Approval of Xtampza ER, an Abuse-Deterrent Analgesic for Chronic Pain - September 11, 2015
- Collegium Announces FDA Advisory Committee Meeting for Xtampza ER, an Abuse-Deterrent Analgesic for Chronic Pain - August 7, 2015
- Collegium Announces FDA Acceptance for Filing of NDA for Abuse-Deterrent Xtampza ER (oxycodone) - February 12, 2015
- Collegium Pharmaceutical Submits NDA for Xtampza ER (oxycodone) Abuse-Deterrent Analgesic - December 15, 2014
Drugs Associated with Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Xtampza ER
Generic name: oxycodone Drug class: narcotic analgesics |
135 reviews | 3.7 / 10 |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||